Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. Canada
  4. Bourse de Toronto
  5. ImmunoPrecise Antibodies Ltd.
  6. Summary
    IPA   CA45257F2008

IMMUNOPRECISE ANTIBODIES LTD.

(IPA)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancials 
Quotes 5-day view   Delayed Quote. Delayed Bourse De Toronto
07/23/2021 07/26/2021 07/27/2021 07/28/2021 07/29/2021 Date
10.71(c) 10.33(c) 9.94(c) 9.24(c) 8.41(c) Last
801 673 345 886 176 251 157 316 203 764 Volume
-35.33% -3.55% -3.78% -7.04% -8.98% Change
More quotes
Estimated financial data (e)
Sales 2020 14,1 M 11,3 M 11,3 M
Net income 2020 -4,95 M -3,98 M -3,98 M
Net Debt 2020 1,90 M 1,53 M 1,53 M
P/E ratio 2020 -10,6x
Yield 2020 -
Sales 2021 17,9 M 14,4 M 14,4 M
Net income 2021 -7,34 M -5,90 M -5,90 M
Net cash position 2021 38,3 M 30,8 M 30,8 M
P/E ratio 2021 -27,2x
Yield 2021 -
Capitalization 162 M 130 M 130 M
EV / Sales 2020 3,93x
EV / Sales 2021 10,8x
Nbr of Employees -
Free-Float 93,3%
More Financials
Company
ImmunoPrecise Antibodies Ltd. is a technology platform company that supports pharmaceutical and biotechnology companies. The Company discover, develop, engineer and manufacture therapeutic antibodies against all classes of disease targets. The Company transforms the conventional multi-vendor antibody discovery model by providing a suite of services tailored to improve antibody genetic diversity and epitope coverage,... 
Sector
Pharmaceuticals
Calendar
10/05Earnings Release
More about the company
All news about IMMUNOPRECISE ANTIBODIES LTD.
07/28IMMUNOPRECISE ANTIBODIES : Reports FY 2020 Results
MT
07/28IMMUNOPRECISE ANTIBODIES : Reports Financial Results and Recent Business Highlig..
PU
07/28IMMUNOPRECISE ANTIBODIES : Annual Report (SEC Filing - 40-F)
PU
07/28IMMUNOPRECISE ANTIBODIES : Reports Financial Results and Recent Business Highlig..
BU
07/22UPDATE : ImmunoPrecise 132% Higher As Publishes Scientific Paper Outlining PolyT..
MT
07/22IMMUNOPRECISE ANTIBODIES : Up 43% As Publishes Scientific Paper Outlining PolyTo..
MT
07/22IMMUNOPRECISE BRIEF : Up More Than 40% As Publishes Scientific Paper 'Cornering ..
MT
07/22IMMUNOPRECISE ANTIBODIES : PolyTope™ TATX-03 Antibody Cocktail Potently Ne..
PU
07/22IMMUNOPRECISE ANTIBODIES : PolyTope™ TATX-03 Antibody Cocktail Potently Ne..
PU
07/22IMMUNOPRECISE ANTIBODIES : PolyTope™ TATX-03 Antibody Cocktail Potently Ne..
BU
07/22ImmunoPrecise Antibodies Ltd. Announces New Results from Its Tatx-03 Polytope..
CI
07/15IMMUNOPRECISE ANTIBODIES : to Report Financial Results and Business Highlights f..
BU
07/15IMMUNOPRECISE ANTIBODIES : to Report Financial Results and Business Highlights f..
PU
06/22IMMUNOPRECISE ANTIBODIES : and Eurofins Discovery Collaborating to Expand Antibo..
MT
06/22IMMUNOPRECISE ANTIBODIES : Eurofins Discovery and ImmunoPrecise Announce Collabo..
PU
More news
News in other languages on IMMUNOPRECISE ANTIBODIES LTD.
07/29IMMUNOPRECISE ANTIBODIES : publie ses résultats financiers et les principaux élé..
07/22IMMUNOPRECISE ANTIBODIES : Le cocktail d'anticorps TATX-03 PolyTope™ d'Imm..
07/15IMMUNOPRECISE ANTIBODIES : s'apprête à présenter ses résultats financiers et les..
06/22IMMUNOPRECISE ANTIBODIES : Eurofins Discovery et ImmunoPrecise annoncent leur co..
06/17IMMUNOPRECISE ANTIBODIES : Des données histopathologiques précliniques du progra..
More news
Chart IMMUNOPRECISE ANTIBODIES LTD.
Duration : Period :
ImmunoPrecise Antibodies Ltd. Technical Analysis Chart | IPA | CA45257F2008 | MarketScreener
Technical analysis trends IMMUNOPRECISE ANTIBODIES LTD.
Short TermMid-TermLong Term
TrendsNeutralNeutralBearish
Income Statement Evolution
Managers and Directors
Jennifer Bath President, Chief Executive Officer & Director
Lisa Helbling Chief Financial Officer
James S. Kuo Chairman
Ilse Roodink Chief Scientific Officer
Gregory S. Smith Independent Director
Sector and Competitors
1st jan.Capi. (M$)
IMMUNOPRECISE ANTIBODIES LTD.-56.74%130
CSL LIMITED2.77%98 032
WUXI BIOLOGICS (CAYMAN) INC.21.21%67 944
SAMSUNG BIOLOGICS CO.,LTD.10.29%52 789
BIOGEN INC.34.43%49 057
ALEXION PHARMACEUTICALS, INC.0.00%40 336